Hello Heart’s CEO Maayan Cohen has been chosen to present in the next 23andMe Future of Phenotyping conference.
The 23andMe cohort is the largest re-contactable research database of genotypic and phenotypic information in the world. By inviting customers to participate in research, they have created a new research model that accelerates genetic discovery and offers the potential to more quickly garnering new insights into treatments for disease. The conference will be held next January 24th in Mountain View, California.
Hello Heart was selected from hundreds of applicants because of its clear and attractive value proposition and operational readiness in the large employer market. The presentation at 23andMe will demonstrate how the Hello Heart solution can benefit large companies and their employees.
Maayan Cohen, Hello Heart’s CEO, will be addressing Hello Heart’s peer-reviewed clinical research.